

Joanna H M Tong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9116767/publications.pdf>

Version: 2024-02-01

51
papers

3,293
citations

186209

28
h-index

189801

50
g-index

51
all docs

51
docs citations

51
times ranked

6132
citing authors

#	ARTICLE	IF	CITATIONS
1	CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein. <i>Molecular Cancer</i> , 2022, 21, 10.	7.9	35
2	Abstract PO-006: CircRTN4 promotes pancreatic cancer progression through a novel circRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein. , 2021, , .		0
3	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 167-181.	4.2	28
4	EBV-encoded miRNAs can sensitize nasopharyngeal carcinoma to chemotherapeutic drugs by targeting BRCA1. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13523-13535.	1.6	11
5	Distinct Molecular Landscape of Epstein-Barr Virus Associated Pulmonary Lymphoepithelioma-Like Carcinoma Revealed by Genomic Sequencing. <i>Cancers</i> , 2020, 12, 2065.	1.7	25
6	FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential. <i>Oncogene</i> , 2020, 39, 6647-6663.	2.6	28
7	Receptor tyrosine kinase fusions act as a significant alternative driver of the serrated pathway in colorectal cancer development. <i>Journal of Pathology</i> , 2020, 251, 74-86.	2.1	9
8	Ectopic HOTTIP expression induces noncanonical transactivation pathways to promote growth and invasiveness in pancreatic ductal adenocarcinoma. <i>Cancer Letters</i> , 2020, 477, 1-9.	3.2	20
9	EGFR mutation exists in squamous cell lung carcinoma. <i>Pathology</i> , 2020, 52, 323-328.	0.3	20
10	LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 811-828.	2.3	19
11	The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1213-1222.	0.5	26
12	Eukaryotic elongation factor-2 kinase expression is an independent prognostic factor in colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 649.	1.1	18
13	A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. <i>Modern Pathology</i> , 2019, 32, 1646-1656.	2.9	16
14	TTPAL Promotes Colorectal Tumorigenesis by Stabilizing TRIP6 to Activate Wnt/ β -Catenin Signaling. <i>Cancer Research</i> , 2019, 79, 3332-3346.	0.4	37
15	The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes. <i>Cancer Research and Treatment</i> , 2019, 51, 706-717.	1.3	10
16	The role of human papillomavirus in laryngeal cancer in Southern China. <i>Journal of Medical Virology</i> , 2018, 90, 1150-1159.	2.5	9
17	miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis. <i>Cell Death and Disease</i> , 2018, 9, 92.	2.7	125
18	Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3. <i>Hepatology</i> , 2018, 67, 2302-2319.	3.6	16

#	ARTICLE	IF	CITATIONS
19	Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma. <i>Modern Pathology</i> , 2018, 31, 1381-1390.	2.9	41
20	Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. <i>Gut</i> , 2018, 67, 931-944.	6.1	138
21	EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma. <i>Journal of Pathology</i> , 2018, 244, 394-407.	2.1	44
22	An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. <i>Nature Communications</i> , 2018, 9, 5214.	5.8	66
23	EXOSC4 functions as a potential oncogene in development and progression of colorectal cancer. <i>Molecular Carcinogenesis</i> , 2018, 57, 1780-1791.	1.3	12
24	Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis. <i>Nucleic Acids Research</i> , 2018, 46, 8832-8847.	6.5	40
25	Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 667-676.	1.4	152
26	Downregulation of long non-coding RNA MEG3 in nasopharyngeal carcinoma. <i>Molecular Carcinogenesis</i> , 2017, 56, 1041-1054.	1.3	59
27	<sc>EZH</sc>2 coupled with <sc>HOTAIR</sc> to silence Micro<sc>RNA</sc>â€³4a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2017, 140, 120-129.	2.3	71
28	Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-â€²B in hepatocellular carcinoma. <i>Journal of Pathology</i> , 2016, 238, 651-664.	2.1	46
29	SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate. <i>Gastroenterology</i> , 2016, 151, 945-960.e6.	0.6	100
30	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. <i>Histopathology</i> , 2016, 69, 971-984.	1.6	21
31	miR-508-3p concordantly silences NFKB1 and RELA to inactivate canonical NF-â€²B signaling in gastric carcinogenesis. <i>Molecular Cancer</i> , 2016, 15, 9.	7.9	63
32	<i>MET</i> Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. <i>Clinical Cancer Research</i> , 2016, 22, 3048-3056.	3.2	352
33	Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1292-1300.	0.5	51
34	Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma. <i>Molecular Cancer</i> , 2015, 14, 52.	7.9	108
35	Epigenetic Silencing of miR-490-3p Reactivates the Chromatin Remodeler SMARCD1 to Promote <i>Helicobacter pylori</i>-Induced Gastric Carcinogenesis. <i>Cancer Research</i> , 2015, 75, 754-765.	0.4	115
36	Lymphoepithelioma-like Hepatocellular Carcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 304-312.	2.1	66

#	ARTICLE	IF	CITATIONS
37	Histone Deacetylase HDAC8 Promotes Insulin Resistance and β -Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma. <i>Cancer Research</i> , 2015, 75, 4803-4816.	0.4	105
38	Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer. <i>Gut</i> , 2015, 64, 636-645.	6.1	163
39	let-7b/g silencing activates AKT signaling to promote gastric carcinogenesis. <i>Journal of Translational Medicine</i> , 2014, 12, 281.	1.8	27
40	Characterization of rare transforming <i>KRAS</i> mutations in sporadic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 768-776.	1.5	61
41	Viral-Human Chimeric Transcript Predisposes Risk to Liver Cancer Development and Progression. <i>Cancer Cell</i> , 2014, 25, 335-349.	7.7	254
42	MCM7 serves as a prognostic marker in diffuse-type gastric adenocarcinoma and siRNA-mediated knockdown suppresses its oncogenic function. <i>Oncology Reports</i> , 2014, 31, 2071-2078.	1.2	21
43	Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma. <i>Oncology Reports</i> , 2014, 31, 2579-2586.	1.2	14
44	Emerging Roles of Small Epstein-Barr Virus Derived Non-Coding RNAs in Epithelial Malignancy. <i>International Journal of Molecular Sciences</i> , 2013, 14, 17378-17409.	1.8	44
45	Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant. <i>Journal of Thoracic Oncology</i> , 2013, 8, 883-891.	0.5	67
46	Paradoxical hypertension and salt wasting in Type II Bartter syndrome. <i>CKJ: Clinical Kidney Journal</i> , 2012, 5, 217-220.	1.4	7
47	Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis. <i>Clinical Cancer Research</i> , 2011, 17, 2130-2139.	3.2	224
48	Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. <i>BMC Cancer</i> , 2010, 10, 253.	1.1	68
49	Modulation of LMP2A Expression by a Newly Identified Epstein-Barr Virus-Encoded MicroRNA miR-BART22. <i>Neoplasia</i> , 2009, 11, 1174-IN17.	2.3	176
50	Correlative Analysis of DNA Methyltransferase Expression and Promoter Hypermethylation of Tumor Suppressor Genes in Hepatocellular Carcinoma. <i>Cancer Genomics and Proteomics</i> , 2006, 3, 271-277.	1.0	2
51	Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. <i>Clinical Cancer Research</i> , 2002, 8, 2612-9.	3.2	63